Following a full submission
AWMSG advice |
|||
| Status: Not recommended | |||
Doxylamine succinate/pyridoxine hydrochloride (Xonvea®) is not recommended for use within NHS Wales for the treatment of nausea and vomiting of pregnancy (NVP) in women who do not respond to conservative management. The cost-effectiveness data presented in the submission were insufficient for AWMSG to recommend its use. This medicine was considered by the AWMSG Scrutiny Panel on 05/03/2026. It was considered suitable for full reassessment by LOWMAG. |
|||
|
|||
Medicine details |
|||
| Medicine name | doxylamine succinate/pyridoxine hydrochloride (Xonvea®) | ||
| Formulation | 10 mg/10 mg film-coated tablet | ||
| Reference number | 2170 | ||
| Indication | Treatment of nausea and vomiting of pregnancy in those patients who do not respond to conservative management |
||
| Company | Alliance Pharmaceuticals Ltd (for original assessment); now Exeltis | ||
| BNF chapter | Central nervous system | ||
| Assessment type | Full | ||
| Status | Not recommended | ||
| Advice number | 0819 | ||
| Scrutiny Panel meeting date | 05/03/2026 | ||
| NMG meeting date | 03/04/2019 | ||
| AWMSG meeting date | 15/05/2019 | ||
| Date of issue | 11/06/2019 | ||
| Date of last review | 05/03/2026 | ||
| Further information This medicine was considered by AWMSG Scrutiny Panel on 05/03/2026. It was considered suitable for a full assessment via the Licensed One Wales Medicines Assessment Group (LOWMAG). This will be reassessment by AWMSG. The company will be asked to submit any supportive evidence to inform the reassessment although it is expected that a full new economic model will not be made available. |
|||